|

Sigvotatug Vedotin Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: PF-08046047, SGN-B6A

Pipeline

Phase 1: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Pfizer2
  • Seagen, a wholly owned subsidiary of Pfizer1

Indications

  • Carcinoma, Non-Small-Cell Lung3
  • Lung Cancer3
  • Cancer3
  • Non Small Cell Lung Cancer2
  • Advanced/Metastatic Non-Small Cell Lung Cancer1

Anchorage, Alaska1 trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Alaska Oncology and Hematology

Phase 1

Fullerton, California1 trial

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center

Phase 3

Orange City, Florida1 trial

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Mid Florida Hematology and Oncology Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.